Search Results
Your search for ,NOt matches 22378 pages
Showing 12201 - 12250When Patients Are Open to Lifestyle Changes: Take Advantage of ‘Unique Window of Opportunity'
Colon cancer survivors who followed guidelines for healthy eating, maintaining a healthy weight, and staying physically active had higher 5-year survival rates than those who did not adhere to those guidelines, according to a study among 992 patients treated with stage III colon cancer.1 The 5-year ...
Following Guidelines for Healthy Eating and Physical Activity May Improve Survival in Patients Treated for Colon Cancer
Following guidelines for proper nutrition, maintaining a healthy weight, and staying physically active may improve survival among patients treated for colon cancer, according to the results of a study with nearly 1,000 patients followed for a median of 7 years.1 “The study suggests that if...
The X-Ray Era: 1901–1915
The text and photographs on this page are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photos below are from the volume titled “The X-Ray Era: 1901–1915.” The photographs...
2018 ASCO: Lenalidomide Plus Rituximab vs Rituximab Plus Chemotherapy in Previously Untreated Follicular Lymphoma
Results from RELEVANCE, a phase III, randomized, open-label, international clinical study conducted in partnership with the Lymphoma Academic Research Organisation (LYSARC), were presented by Fowler et al at the 2018 ASCO Annual Meeting (Abstract 7005). This study evaluated the investigational...
FDA Approves Biosimilar to Pegfilgrastim to Reduce Risk of Infection During Myelosuppressive Chemotherapy
On June 4, the U.S. Food and Drug Administration (FDA) approved pegfilgrastim-jmdb (Fulphila) as the first biosimilar to pegfilgrastim (Neulasta) to decrease the chance of infection as suggested by febrile neutropenia in patients with nonmyeloid cancer who are receiving myelosuppressive...
2018 ASCO: Olaparib in Combination With Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Data presented by Clarke et al at the 2018 ASCO Annual Meeting (Abstract 5003) showed clinical improvement in median radiologic progression-free survival with olaparib (Lynparza) in combination with abiraterone (Yonsa, Zytiga) compared to abiraterone monotherapy, a current standard of care, in...
2018 ASCO: Pembrolizumab Plus Chemotherapy as First-Line Treatment of Metastatic Squamous NSCLC: KEYNOTE-407 Study
Results from KEYNOTE-407, a randomized, double-blind, placebo-controlled, phase III study evaluating pembrolizumab (Keytruda) in combination with carboplatin/paclitaxel or carboplatin/nab-paclitaxel (Abraxane) as first-line treatment for metastatic squamous non–small cell lung cancer...
Tai Chi for the Treatment of Insomnia in Breast Cancer Survivors
Underrecognized and inadequately managed, insomnia is a significant burden for many cancer survivors. Often persistent over several years following diagnosis and treatment, sleep problems negatively affect quality of life and elevate the risk of depression and anxiety. In this installment of The...
ASCO Supports NCI-Designated Cancer Centers’ Goal of Eliminating HPV-Related Cancers
ASCO has endorsed a statement by the 70 National Cancer Institute (NCI)-designated cancer centers calling for increased human papillomavirus (HPV) vaccination and screening to eliminate HPV-related cancers. The full uptake of the vaccine and screening could prevent 12,000 cervical cancers and...
AAMC Study Examines Career Trends Among MD-PhD Program Graduates
There is a projected decline in the physician-scientist workforce, according to a new study published by the Association of American Medical Colleges (AAMC). The report, the National MD-PhD Program Outcomes Study, tracks the careers of MD-PhD program graduates over 50 years (1964–2014) and...
St. Baldrick’s Foundation and SU2C Support Pediatric Cancer Research
The collaboration between Stand Up To Cancer (SU2C) and St. Baldrick’s Foundation Pediatric Cancer, launched in 2013, continues to help develop new immunotherapy approaches to high-risk childhood cancers, with the most recent donation of $8 million from the St. Baldrick’s Foundation. In addition,...
Inside Look at Widowers Coping With Grief
BOOKMARK Title: The Group: Seven Widowed Fathers Reimagine LifeAuthors: Donald L. Rosenstein, MD, and Justin M. Yopp, PhDPublisher: Oxford University PressPublication Date: January 2018Price: $28.95; hardcover, 192 pages Looking back, the cancer advocacy movement took shape in two waves: the first ...
Dabrafenib Plus Trametinib for Thyroid Cancer, Melanoma With BRAF Mutations
On May 4, 2018, dabrafenib (Tafinlar) and trametinib (Mekinist) in combination was granted approval for treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation and no satisfactory locoregional treatment options.1-3 Dabrafenib is not indicated for ...
Hematopoietic Cell Transplantation for Follicular Lymphoma
Many patients with follicular lymphoma relapse within 2 years of initial therapy, and for a number of these individuals, hematopoietic cell transplantation is a good treatment option. Transplant, however, both autologous and allogeneic, is vastly underutilized in these patients, according to Mehdi ...
Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma: A Shift in the Treatment Paradigm
For over a decade, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors have been the standard first-line agents in the management of patients with advanced or metastatic clear cell renal cell carcinoma.1-3 Historically, phase III trials of first-line VEGF therapies included...
CheckMate 214: Nivolumab Plus Ipilimumab Improves Survival vs Sunitinib in Advanced Renal Cell Cancer
As reported in The New England Journal of Medicine by Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, the phase III CheckMate 214 trial has shown an overall survival advantage with nivolumab (Opdivo) plus ipilimumab (Yervoy) vs sunitinib (Sutent) in patients with...
2018 ASCO: Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
For patients with multiple myeloma who have been treated with lenalidome (Revlimid) but have relapsed and not responded to other therapy, a three-drug combination can significantly extend the time in which the disease is held in check. The findings of the phase III OPTIMISMM trial were presented by ...
2018 ASCO: KEYNOTE-427 Trial Evaluates Immunotherapy in Advanced Clear Cell Renal Cell Carcinoma
Interim results from cohort A of KEYNOTE-427, a phase II trial evaluating pembrolizumab (Keytruda) as first-line treatment for advanced clear cell renal cell carcinoma (RCC), were presented by McDermott et al at the 2018 ASCO Annual Meeting (Abstract 4500). Interim data showed an overall response...
2018 ASCO: 2-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses With Avelumab
Updated efficacy and safety data from the international, multicenter JAVELIN Merkel 200 trial of avelumab (Bavencio) in patients with metastatic Merkel cell carcinoma were presented by Nghiem et al at the 2018 ASCO Annual Meeting (Abstract 9507). 2-Year Follow-up At the 2-year follow-up update of ...
2018 ASCO: Erdafitinib Shows Activity in FGFR3-Mutated Urothelial Cancer
In an international phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with the oral FGFR inhibitor erdafitinib was well tolerated and achieved a robust response for patients with metastatic urothelial cancers harboring mutations in the FGFR3...
2018 ASCO: Pexidartinib in Tenosynovial Giant Cell Tumor
The phase III ENLIVEN study showed a statistically significant 39% overall response rate at week 25 based on central review of magnetic resonance imaging (MRI) scans using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 (the primary endpoint) for patients treated with oral...
ASCO 2018: Updated ALEX Trial Results on Alectinib in Treatment-Naive ALK Mutation–Positive NSCLC
Updated results of the global phase III ALEX trial comparing alectinib (Alecensa) with crizotinib (Xalkori) as first-line treatment against ALK-positive non–small cell lung cancer (NSCLC) show a median progression-free survival of 34.8 months in 152 patients treated with alectinib vs 10.9...
2018 ASCO: Neoadjuvant Use of PARP Inhibitor Shows Promise in Early-Stage, BRCA-Mutated Breast Cancer
In a small phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers at The University of Texas MD Anderson Cancer Center found that more than half of the women who took the PARP inhibitor talazoparib once daily prior to surgery had no evidence of disease at the time...
2018 ASCO: iNNOVATE Trial Evaluates Ibrutinib in Combination With Rituximab in Patients With Waldenström's Macroglobulinemia
Results from a preplanned interim analysis of the phase III iNNOVATE (PCYC-1127) study evaluating the investigational use of ibrutinib (Imbruvica) in combination with rituximab (Rituxan) in relapsed/refractory and treatment-naive patients with Waldenström’s macroglobulinemia were...
FDA Approves First Biosimilar to Pegfilgrastim to Help Reduce the Risk of Infection During Myelosuppressive Chemotherapy
On June 4, the U.S. Food and Drug Administration (FDA) approved pegfilgrastim-jmdb (Fulphila) as the first biosimilar to pegfilgrastim (Neulasta) to decrease the chance of infection as suggested by febrile neutropenia in patients with nonmyeloid cancer who are receiving myelosuppressive...
2018 ASCO: Esomeprazole With Aspirin Offers Moderate Benefits in Patients With Barrett’s Esophagus
An updated analysis of a randomized phase III trial showed that taking a high dose of the acid-reducing medicine esomeprazole with low-dose aspirin for at least 7 years can moderately reduce the risk of developing high-grade dysplasia or esophageal cancer and delay death from any cause in people...
2018 ASCO: Adjuvant mFOLFIRINOX vs Gemcitabine in Resected Pancreatic Cancer
In a randomized phase III trial, patients with surgically removed pancreatic cancer who received mFOLFIRINOX (a modified regimen containing oxaliplatin, leucovorin, irinotecan, and fluorouracil) lived a median of 20 months longer and were cancer-free 9 months longer than those who received the...
2018 ASCO: Hyperthermic Intraperitoneal Chemotherapy Does Not Add Benefit in Patients With Advanced Colorectal Cancer
A randomized phase III clinical trial showed that people with advanced colorectal cancer may not need a frequently considered component of treatment—heated chemotherapy delivered to the abdomen during surgery. There was no difference in survival between patients with metastases in the abdomen ...
2018 ASCO: Carmena Trial Compares Nephrectomy Plus Adjuvant Sunitinib vs Sunitinib Alone in Metastatic RCC
The randomized phase III Carmena trial showed that many people with advanced kidney cancer can avoid nephrectomy without compromising survival. The median overall survival for people who received the targeted therapy sunitinib (Sutent) alone was 18.4 months, compared with 13.9 months for those who...
2018 ASCO: TAILORx: Most Women With Early-Stage Breast Cancer Can Forgo Chemotherapy When Guided by a Diagnostic Test
The federally funded, phase III TAILORx clinical trial showed that most women with hormone receptor (HR)–positive, HER2-negative, axillary node–negative early-stage breast cancer and a mid-range score on a 21-tumor gene expression assay (Oncotype DX® Breast Recurrence Score) do not...
2018 ASCO: KEYNOTE-042 Trial Compares Pembrolizumab With Chemotherapy as First-Line Treatment of NSCLC With PD-L1 Expression of 1% or More
A large, randomized phase III trial shows that the immunotherapy pembrolizumab (Keytruda) is a more effective initial treatment than chemotherapy (the current standard of care) for the majority of patients with the most common type of lung cancer. People with advanced non–small cell lung...
2018 ASCO: Phase III SANDPIPER Trial Evaluates Taselisib Plus Fulvestrant in Advanced Breast Cancer
In a phase III clinical trial, the investigational PI3K inhibitor taselisib combined with standard hormone therapy fulvestrant (Faslodex) halted the growth of advanced breast cancer growth by 2 months longer than hormone therapy alone. In addition, the novel combination decreased the chance of...
2018 ASCO: Blood Test Shows Potential as a Detection Tool for Early-Stage Lung Cancer
An initial report from the large, ongoing Circulating Cell-Free Genome Atlas (CCGA) study provides preliminary evidence that a blood test may be able to detect early-stage lung cancer. This is one of the first studies to explore blood tests analyzing free-floating or cell-free DNA as a tool for the ...
2018 ASCO: IMpower 131 Studies Addition of Atezolizumab to Chemotherapy in Advanced Squamous NSCLC
Initial findings from a randomized phase III clinical trial showed that patients with advanced squamous non–small cell lung cancer (NSCLC) benefit more from initial treatment with the programmed cell death ligand 1 (PD-L1)-targeted immunotherapy atezolizumab (Tecentriq) and chemotherapy than...
2018 ASCO: Genomic Study Finds Lynch Syndrome Is Common Among Patients With MSI-High Tumors
A genomic study of more than 15,000 tumor samples showed that people who have tumors with high microsatellite instability (MSI-H)—a genomic marker associated with a large number of genetic mutations in the tumor—are more likely to have Lynch syndrome, a hereditary condition that...
2018 ASCO: IMPACT Trial Matches Treatment to Genetic Changes in the Tumor to Improve Survival Across Multiple Cancer Types
Researchers conducted a retrospective analysis of consecutive, prospectively molecularly profiled patients with advanced cancer who participated in a large, personalized medicine trial. They found that using molecular tests of tumors to select targeted therapy resulted in slower cancer growth and...
2018 ASCO: Abiraterone May Be More Effective in Black Men With Advanced Prostate Cancer Than in White Men
In a prospective clinical trial of 100 men with metastatic castration-resistant prostate cancer, the response to the hormone treatment abiraterone (Yonsa, Zytiga) was greater and longer-lasting in black men than in white men. Black men were more likely to have a decline in prostate-specific antigen ...
2018 ASCO: Gender Disparities in Head and Neck Cancer Treatment and Outcomes
An analysis of cancer registry data from a California hospital system showed that women with head and neck cancer were less likely to receive intensive chemotherapy (35% vs 46%) and radiation (60% vs 70%) compared to men. Controlling for factors such as age and serious medical conditions, a...
2018 ASCO: Geriatric Assessment Improves Communication Between Oncologists and Older Patients
A federally funded randomized study demonstrated that the use of geriatric assessment in routine care of older adults with advanced cancer significantly improved doctor-patient communication about age-related concerns as well as patient satisfaction with the communication. The study was featured in ...
2018 ASCO: Treatment for Colorectal Cancer in Washington State Costs Twice as Much as in Neighboring Area of Canada, Despite No Difference in Survival
An analysis of health claims data from two demographically similar regions on either side of the U.S./Canada border shows that a common treatment for advanced colorectal cancer costs twice as much in Western Washington State than in British Columbia—$12,345 vs $6,195 monthly per patient....
American Cancer Society Updates Colorectal Cancer Screening Guideline
An updated American Cancer Society guideline now says colorectal cancer screening should begin at age 45 for people at average risk, based in part on data showing rates of colorectal cancer are increasing in young and middle-aged populations. The updated recommendations were published by Wolf et al ...
Safety of PD-1/PD-L1 Inhibitors in Patients With NSCLC and Preexisting Autoimmune Disorders
In a study reported in the Journal of Clinical Oncology, Leonardi et al found that programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor monotherapy in patients with non–small cell lung cancer (NSCLC) and autoimmune disorders worsened such disorders in a...
Multiple-Gene Sequencing vs BRCA1/2-Only Testing After Breast Cancer Diagnosis
In a retrospective cohort study reported in JAMA Oncology, Kurian et al found that use of germline multiple-gene sequencing has become more common than BRCA1/2-only sequencing after breast cancer diagnosis in clinical practice, with an associated increased detection of pathologic variants not...
Former Chair of ASCO’s Health Disparities Committee, Karen M. Winkfield, MD, PhD, Faced Her Own Barriers
Nationally regarded radiation oncologist Karen M. Winkfield, MD, PhD, was born and reared in Wheatley Heights, a suburban hamlet on Long Island, New York, that shares borders with the prosperous community of Dix Hills and one of the Island’s lowest-income towns, Wyandanch. “I was fortunate to live ...
Noted Oncologist Narayanankutty Warrier, MD, Battles Tobacco Use and Builds a Cancer Center in India
India, with the world’s second-largest population and more than 2,000 ethnic groups, is a vastly complex nation, noted for its rich history and boundless intellectual capital, but also for its poverty and inequities in areas such as access to health care. The State of Kerala, situated in the...
ASCO, ABIM Collaborate on Pathway to Maintenance of Board Certification
ASCO and the American Board of Internal Medicine (ABIM) have announced that they are working to co-create a pathway to provide doctors with a flexible way to maintain board certification. The work with ASCO reflects real progress in ABIM’s efforts to collaborate with medical societies. Beginning in ...
Valued Mentors and a Link Between Science and Medicine Paved the Road to Oncology for Alice Tsang Shaw, MD, PhD
Lung cancer expert Alice Tsang Shaw, MD, PhD, was born and reared in Gaithersburg, a small suburb located to the northwest of Washington, DC. Both her parents were chemists, and during high school, Dr. Shaw had a keen interest in science, particularly biology, yet the thought of pursuing a career...
NIH Completes In-Depth Genomic Analysis of 33 Cancer Types
Researchers funded by the National Institutes of Health (NIH) have completed a detailed genomic analysis, known as the PanCancer Atlas, on a data set of molecular and clinical information from over 10,000 tumors representing 33 types of cancer, according to a release issued by the NIH late last...
A Love of Science Leads to an Esteemed Career in Cancer Research for Razelle Kurzrock, MD
Razelle Kurzrock, MD, regarded internationally for her work in translational science, was born and reared in Toronto, Canada. “My parents were immigrants from Eastern Europe. My father, who was Jewish, was a Holocaust survivor. My parents put a strong emphasis on education,” she said. ‘The...
FDA Oncology Drug Approvals Granted Between June 2017 and May 16, 2018
Over the past year (June 2017–May 2018), the U.S. Food and Drug Administration (FDA) granted approval to a number of new oncology drug products, including several biosimilar products. Here we provide the labeling approved for these novel drugs and new indications. EPOETIN ALFA-EPBX (RETACRIT)...
